COVID-19 Outcomes in Solid Organ Transplant Recipients Who Received Tixagevimab-cilgavimab Prophylaxis and/or Bebtelovimab Treatment in a Nurse-driven Monoclonal Antibody Program During the Omicron Surge

Transplantation. 2023 Feb 1;107(2):e60-e61. doi: 10.1097/TP.0000000000004418. Epub 2022 Oct 13.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antibodies, Monoclonal
  • COVID-19* / prevention & control
  • Humans
  • Organ Transplantation* / adverse effects
  • Transplant Recipients

Substances

  • tixagevimab
  • cilgavimab
  • bebtelovimab
  • Antibodies, Monoclonal